National Clinical Target Validation Laboratory, Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Building, 37/Room 1048, 37 Convent Drive, Bethesda, MD 20892 USA.
Expert Rev Anticancer Ther. 2009 Dec;9(12):1715-25. doi: 10.1586/era.09.153.
Bevacizumab is a humanized monoclonal antibody to VEGF, and the incorporation of bevacizumab to chemotherapy is one of the rapidly evolving areas in the treatment of breast cancer. Bevacizumab in combination with chemotherapy versus chemotherapy alone improves progression-free survival and increases the response rate in first-line therapy for locally recurrent or metastatic breast cancer. This approach has been and is still being evaluated for early breast cancer in neoadjuvant and adjuvant settings. Bevacizumab is well tolerated and has an established tolerability profile. Both tumor- and host-related biomarkers of bevacizumab activity, response and benefit are emerging from Phase I, II and III clinical trials. The biomarkers of benefit will ultimately help identify the subgroups of patients who specifically benefit from anti-VEGF therapy with bevacizumab.
贝伐珠单抗是人源化抗血管内皮生长因子（VEGF）单克隆抗体，贝伐珠单抗联合化疗是乳腺癌治疗中迅速发展的领域之一。贝伐珠单抗联合化疗对比单纯化疗，可改善局部复发或转移性乳腺癌患者的无进展生存期并提高缓解率。该方案已在局部复发或转移性乳腺癌的新辅助和辅助治疗中进行了评估，且仍在评估早期乳腺癌患者的应用。贝伐珠单抗耐受性良好，具有明确的可耐受特征。贝伐珠单抗的活性、疗效和获益的肿瘤相关和宿主相关生物标志物，正不断从 I 期、II 期和 III 期临床试验中涌现。获益的生物标志物最终将有助于确定哪些亚组患者可特异性地从贝伐珠单抗的抗血管内皮生长因子治疗中获益。
